This clinical trial is focused on studying the effects of certain medications used after a kidney transplant, specifically in patients with chronic kidney disease. The medications being studied are Tacrolimus and mycophenolate mofetil. These drugs are commonly used to prevent the body from rejecting a new kidney after a transplant. The purpose of the study is to understand how these medications interact with the gut microbiota, which is the community of microorganisms living in the digestive tract, and how this interaction affects the way the body processes these drugs.

Participants in the study will receive either Tacrolimus or mycophenolate mofetil, or a combination of both, as part of their regular treatment after a kidney transplant. The study will observe changes in the gut microbiota and how these changes might influence the effectiveness and processing of the medications. The study will also involve monitoring the participants over a period of time to gather data on how the medications are absorbed and metabolized in the body.

The study aims to provide insights into the variability of how different patients respond to these immunosuppressant drugs, which are crucial for the success of kidney transplants. By understanding these differences, the study hopes to improve treatment plans and outcomes for future patients undergoing kidney transplants. Participants will be monitored closely throughout the study to ensure their safety and to collect necessary data for the research.